Your browser doesn't support javascript.
loading
Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction.
Sanderson, John E; Fang, Fang; Lu, Mi; Ma, Chen Yao; Wei, Yong Xiang.
Afiliação
  • Sanderson JE; Beijing Institute of Heart, Lung, and Blood diseases, Capital Medical University Affiliated Anzhen Hospital, Beijing, Chaoyang-qu, China.
  • Fang F; Beijing Institute of Heart, Lung, and Blood diseases, Capital Medical University Affiliated Anzhen Hospital, Beijing, Chaoyang-qu, China fangfang_ff@hotmail.com.
  • Lu M; Beijing Institute of Heart, Lung, and Blood diseases, Capital Medical University Affiliated Anzhen Hospital, Beijing, Chaoyang-qu, China.
  • Ma CY; Beijing Institute of Heart, Lung, and Blood diseases, Capital Medical University Affiliated Anzhen Hospital, Beijing, Chaoyang-qu, China.
  • Wei YX; Beijing Institute of Heart, Lung, and Blood diseases, Capital Medical University Affiliated Anzhen Hospital, Beijing, Chaoyang-qu, China.
Heart ; 107(3): 190-194, 2021 02.
Article em En | MEDLINE | ID: mdl-33158933
ABSTRACT
Obstructive sleep apnoea (OSA) is recognised to be a potent risk factor for hypertension, coronary heart disease, strokes and heart failure with a reduced ejection fraction. However, the association between OSA and heart failure with a preserved ejection fraction (HFpEF) is less well recognised. Both conditions are very common globally.It appears that there are many similarities between the pathological effects of OSA and other known aetiologies of HFpEF and its postulated pathophysiology. Intermittent hypoxia induced by OSA leads to widespread stimulation of the sympathetic nervous system, renin-angiotensin-aldosterone system and more importantly a systemic inflammatory state associated with oxidative stress. This is similar to the consequences of hypertension, diabetes, obesity and ageing that are the common precursors to HFpEF. The final common pathway is probably via the development of myocardial fibrosis and structural changes in collagen and myocardial titin that cause myocardial stiffening. Thus, considering the pathophysiology of OSA and HFpEF, OSA is likely to be a significant risk factor for HFpEF and further trials of preventive treatment should be considered.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Volume Sistólico / Apneia Obstrutiva do Sono / Insuficiência Cardíaca / Hipóxia Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Volume Sistólico / Apneia Obstrutiva do Sono / Insuficiência Cardíaca / Hipóxia Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article